Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AbbVie Expands With Singapore Site
by Ann M. Thayer
February 10, 2014
| A version of this story appeared in
Volume 92, Issue 6
AbbVie will spend $320 million to build a plant in Singapore for small-molecule and biologic active pharmaceutical ingredient manufacturing. The drug company will use the new facility to make oncology and immunology products in its development pipeline. The site will be AbbVie’s first manufacturing location in Asia. It already has about 120 people in Singapore to support commercial operations and R&D, and will add another 250 when the plant is fully operational in 2019. The company also has R&D operations in Tokyo and in Shanghai.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter